What CGM sensor drift actually is — and why it is structurally inevitable

CGM sensor drift is a progressive, systematic shift in a sensor’s electrochemical sensitivity to glucose that accumulates over the sensor wear period, producing readings that are biased — not merely noisy — relative to true blood glucose. The bias arises from four interacting sources identified in the foundational patent literature: physiology, sensor calibration, noise, and engineering. Because all four operate simultaneously and evolve independently, drift is not an incidental defect but a structural property of amperometric interstitial glucose sensing that every CGM system must explicitly model and correct.

At the electrochemical level, an amperometric glucose sensor generates a current proportional to glucose concentration via the enzymatic oxidation of glucose by glucose oxidase. The sensitivity of this reaction depends on three coupled variables: the enzymatic activity of the glucose oxidase layer, the permeability of the outer diffusion-limiting membrane, and the biological tissue response at the insertion site. All three degrade continuously and non-linearly during sensor wear. Enzymatic activity declines due to denaturation and fouling; membrane permeability shifts as proteins adsorb onto the sensor surface; and the tissue response — including local inflammation and fibrous encapsulation — alters the diffusion pathway between the interstitial fluid and the sensing element.

A physiological complication compounds the engineering problem: the glucose concentration in interstitial fluid (ISF) does not track blood glucose (BG) instantaneously. There is a physiological time lag between the two compartments that changes dynamically with time, glucose levels, and across subjects. This lag creates a form of apparent drift in naive implementations — the sensor signal may appear to lead or lag true glucose changes in ways that resemble systematic bias but are actually kinetic. Separating this physiological lag from true electrochemical drift is one of the central algorithmic challenges in CGM design, as documented across multiple University of Virginia Patent Foundation filings.

End-of-life drift represents the most extreme manifestation of sensitivity loss. Calibration algorithms must compute a “downward drift” metric — the error at calibration — which is normalized for irregular calibration timing and smoothed via moving average or exponential smoothing to quantify end-of-life symptoms and generate a risk factor metric value. This systematic tracking of drift magnitude therefore serves both as a correction input and as a sensor termination criterion, as described in a 2023 WO filing by Naggs.

An additional, often underappreciated driver of apparent drift is physical compression of the sensor at the insertion site. Research from the University of Virginia Patent Foundation demonstrates that mechanical pressure produces signal attenuation artifacts — pressure-induced sensor attenuations (PISAs) — that are clinically significant and algorithmically distinct from electrochemical drift. A Chinese innovation from Chongqing Lianxin Zhikang Biotech addresses nocturnal non-physiological signal depressions using a dual-dimension discrimination logic: time-domain feature extraction first classifies whether a signal segment constitutes a short-term depression, then physiological-dimension rules verify whether it corresponds to true hypoglycemia — preventing the masking of genuine hypoglycemic events.

“CGM readings are noisy and affected by significant bias — and the deterioration in sensor accuracy over time must be embedded as a core algorithmic input, not treated as an afterthought.”

Factory-embedded drift profiles: correcting drift before the sensor is inserted

Factory calibration is the most upstream algorithmic correction strategy available to CGM developers: it encodes each sensor’s predicted drift trajectory into the algorithm before the device ever contacts a patient. Zense-Life Inc. has pioneered this approach with US and WO filings in 2024 that disclose a method in which a processor automatically generates a correlation between enzyme membrane thickness, glucose-limiting membrane thickness, and working wire diameter — measured during manufacturing — and at least one of a factory sensitivity value or a drift profile.

The architecture is straightforward in principle but technically demanding in execution. Multiple drift profiles are embedded in a cloud-based algorithm platform. Based on manufacturing data — enzyme membrane thickness and initial sensitivity measurements — specific profiles are assigned to individual sensors to optimise long-term performance. Critically, the greater the initial sensor slope (sensitivity), the more predictable and correctable the long-term drift behavior, which provides a manufacturing quality signal that feeds directly into algorithm selection. This approach eliminates the need for patient-side calibration against fingerstick blood glucose for initial sensor setup, aligning with the industry’s trajectory toward zero-calibration devices.

A complementary strategy from Chongqing Lianxin Zhikang Biotech (CN, 2026) uses factory-verified sensitivity as a core input parameter for a nonlinear compensation model. By explicitly encoding each sensor’s initial response characteristics into the blood glucose estimation model, the approach eliminates the root cause of inter-sensor variability arising from differences in enzyme activity and production process — reducing the need for repeated manual calibration throughout the sensor’s operational life. This nonlinear framing is significant: it acknowledges that the relationship between manufacturing parameters and in-vivo drift is not linear, and that simple scalar corrections are insufficient for sensors with high manufacturing variability.

Time-dependent compensation and signal-only self-calibration

Time-dependent drift compensation functions — applied to raw sensor output during the wear period — are the most broadly deployed algorithmic correction mechanism in the CGM patent landscape. Dexcom’s core approach, described in a 2016 US filing, converts raw sensor data to analyte sensor data using a conversion function, then applies a drift compensation function to compensate for changes in sensor responsiveness over time. The same patent addresses a critical corner case: sensor reuse. If the system assumes all initialized sensors are new, it may apply incorrect calibration assumptions to a reused sensor, producing artificially inflated or deflated glucose readings. Detecting reuse and applying the appropriate sensitivity profile is therefore a non-trivial algorithmic requirement.

For signal-level self-calibration without fingerstick reference measurements, Dexcom’s AU 2024 filing describes a technique using forward and backward filters applied to the sensor signal, optimising seed parameters to minimise mean squared error between the two filters. The calibration then adjusts sensor sensitivity and baseline according to criteria that include consistency of mean glucose with expected diabetic population means and consistency of glucose variability with the measured mean glucose level. This “signal-only” approach is strategically important because it enables fully factory-calibrated, no-fingerstick CGM systems — a key competitive differentiator as the industry moves toward implantable and long-wear devices. Standards bodies including ISO are actively developing accuracy requirements for such calibration-free systems under ISO 15197.

Tandem Diabetes Care’s 2016 US filing introduces a predictive variant: the system generates calibration curves from at least two measured data values and determines a transformation function that extrapolates to produce a predictive calibration curve. Rather than only correcting for past drift, the system anticipates how the calibration curve will evolve and uses the predicted curve to estimate current glucose values. This forward-looking approach reduces the lag between actual drift and algorithmic compensation — a meaningful clinical benefit given that uncorrected drift during rapid glucose change can trigger false alarms or missed alerts.

Ascensia’s approach, described in a TW 2026 filing, introduces probe potential modulation sequences applied to the sensor alongside a constant voltage potential. The resulting primary current signal and probe modulation current signal are used together through a “connection function” to derive a final glucose concentration, enabling real-time, model-driven compensation of both sensitivity drift and baseline shift within a single measurement cycle. The University of Virginia’s approach to noise and physiological lag — described in a CA 2023 filing — estimates the CGM signal at a future time t+PH (prediction horizon) using the current CGM value at time t, with a noise estimation algorithm. The prediction horizon is kept below 20 minutes to maintain clinical relevance while effectively denoising the signal. Authoritative guidance on CGM performance standards is available from the FDA and the WHO, both of which publish frameworks for evaluating glucose monitoring accuracy in clinical settings.

Machine learning, pressure artifacts, and orthogonal redundancy

Machine learning models have become a primary tool for classifying drift-related artifacts and separating them from true physiological glucose changes. Medtronic MiniMed’s EP 2022 filing describes ML models trained to classify CGM sensor data and blank data points flagged as outliers, using multi-dimensional input signals — including interstitial current signal (Isig), electrochemical impedance spectroscopy (EIS), and counter voltage (Vcntr) — rather than univariate signal analysis. This multi-signal approach enables far more reliable classification of sensor error conditions including drift, because EIS provides direct chemical information about the state of the sensor membrane that cannot be inferred from glucose current alone.

The University of Virginia Patent Foundation’s PISA detection work — filed across US, WO, AU, JP, and CN — represents the most comprehensive algorithmic treatment of physical artifact-driven drift in the dataset. The US 2024 filing uses a first ML model to identify candidate glucose time series containing compression artifacts and a second ML model to confirm whether those measurements were taken while the sensor was subject to compression — providing a two-stage artifact classification pipeline. A companion system uses a clearance value computed between baseline BG measurements and current BG measurements, flagging compression when the clearance value exceeds a predefined threshold in real time.

Dexcom’s JP 2024 adaptive CGM filing incorporates accelerometer-derived orientation data to identify the physical location of the sensor insertion site and corrects glucose values based on that location — addressing the underappreciated problem that insertion site physiology (abdominal vs. arm placement) systematically influences sensor output and drift characteristics. This hardware-software integration reflects a broader trend: as noted by WIPO in its technology trend reports on medical devices, the convergence of sensor hardware innovation with algorithmic intelligence is accelerating across the diagnostics sector.

Medtronic MiniMed’s orthogonal redundancy strategy — described in CA and WO 2015 filings — combines optical and electrochemical measurement modalities in a single sensor system. Integrity checks are performed on sensor glucose values from both modalities, explicitly checking for sensitivity loss, noise, and drift before calibration is applied. If integrity checks are failed, in-line sensor mapping between the two sensor types is performed prior to calibration. The two sensor glucose values are then weighted by their respective reliability index (RI) and fused into a single combined output. This approach provides an intrinsic self-consistency validation that single-sensor architectures fundamentally cannot achieve.

“Orthogonal redundancy — using both optical and electrochemical sensors in parallel — provides an intrinsic drift self-check that single-modality systems cannot replicate.”

Shenzhen Kefu Biotech’s CN 2024 deep learning system applies supervised training on sensor decay data segmented by attenuation characteristics. The system uses piecewise fitting via least squares to model the initial glucose concentration dataset during the attenuation period, then applies data mining constraints on individual sensors to prevent over-calibration — which can introduce errors larger than the drift itself. This two-layer approach reflects the emerging consensus that purely global correction models are insufficient for manufacturing-variable sensors: population-level model training must be combined with individual sensor constraints to avoid the over-correction problem.

The patent landscape: who is building the IP moat

The CGM sensor drift correction patent landscape, spanning approximately 50 sources from 2007 through early 2026 across jurisdictions including the US, EP, WO, AU, JP, CN, CA, IT, TW, and ES, reveals a field dominated by a small number of well-resourced incumbents but increasingly contested by academic institutions and emerging Chinese innovators.

Dexcom, Inc. is the dominant patent holder, with filings spanning time-dependent drift compensation, self-calibration using signal-only algorithms, retrospective retrofitting, and adaptive sensor systems. The company’s trajectory reflects a deliberate strategy of eliminating user-facing calibration by embedding sophisticated drift correction into factory processes and sensor electronics. Multi-year continuation families on core drift compensation methods underscore the depth of this IP position. Dexcom’s work is consistent with the broader regulatory direction signalled by bodies such as the FDA, which has approved several Dexcom systems for use without adjunctive fingerstick confirmation.

University of Virginia Patent Foundation is the most prolific academic contributor, with a broad portfolio spanning noise estimation, PISA detection, data compression, and HbA1c modeling from CGM data. The PISA detection work filed across five jurisdictions represents the most comprehensive algorithmic treatment of physical artifact-driven drift in the dataset — and is notable for its two-stage ML pipeline architecture, which may serve as a template for other artifact classes.

Medtronic MiniMed, Inc. has patented redundant sensor architectures with cross-modality drift detection, alongside ML-based outlier classification systems that incorporate EIS — an approach that provides chemical information about the sensor membrane state beyond what can be inferred from glucose current alone. Ascensia Diabetes Care Holdings AG has filed across US, WO, and TW for gain-function-based real-time compensation approaches using historical signal windows. Zense-Life Inc. has carved a specific niche in factory calibration and pre-assigned drift profiles, with filings in US, WO, and CN.

The emerging cluster of Chinese innovators — Chongqing Lianxin Zhikang Biotech and Shenzhen Kefu Biotech — are applying nonlinear compensation models, deep learning, and adaptive calibration to address both inter-sensor manufacturing variability and intra-individual physiological drift. Their 2024–2026 filings suggest that domestic Chinese CGM development is moving beyond simple replication of Western approaches toward novel algorithmic architectures, particularly in the areas of piecewise attenuation modeling and dual-dimension depression discrimination. This trend is consistent with the broader innovation dynamics tracked by WIPO in its annual IP statistics, which show China as the world’s largest filer of medical device patents as of recent reporting periods. For IP professionals monitoring this space, PatSnap’s patent discovery tools and life sciences intelligence platform provide comprehensive coverage of both Western and Asian filings in this domain.